Predictors of survival in patients with bone metastasis of lung cancer.

Predictors of survival in patients with bone metastasis of lung cancer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Predictors of survival in patients with bone metastasis of lung cancer. Abstract Text:

Hideshi Sugiura,Kenji Yamada,Takahiko Sugiura,Toyoaki Hida,Tetsuya Mitsudomi,Hideshi Sugiura,Kenji Yamada,Takahiko Sugiura,Toyoaki Hida,Tetsuya Mitsudomi,

The prognosis of patients with bone metastasis from lung cancer has not been well documented. We assessed the survival rates after bone metastasis and prognostic factors in 118 patients with bone metastases from lung cancer. The cumulative survival rates after bone metastasis from lung cancer were 59.9% at 6 months, 31.6% at 1 year, and 11.3% at 2 years. The mean survival was 9.7 months (median, 7.2 months; range, 0.1-74.5 months). A favorable prognosis was more likely in women and patients with adenocarcinoma, solitary bone metastasis, no metastases to the appendicular bone, no pathologic fractures, performance status 1 or less, use of systemic chemotherapy, and use of an epithelial growth factor receptor inhibitor. Analyses of single and multiple variables indicated better prognoses for patients with adenocarcinoma, no evidence of appendicular bone metastases, and treatment with an epithelial growth factor receptor inhibitor. The mean survival period was longer in a small group treated with an epithelial growth factor receptor inhibitor than in the larger untreated group. The data preliminarily suggest treatment with an epithelial growth factor receptor inhibitor may improve survival after bone metastasis. Level of Evidence: Level IV, prognostic study. See the Guidelines for Authors for a complete description of levels of evidence.

Predictors of survival in patients with bone metastasis of lung cancer. Publishing Authors By Initials

H Sugiura,K Yamada,T Sugiura,T Hida,T Mitsudomi,H Sugiura,K Yamada,T Sugiura,T Hida,T Mitsudomi,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Predictors of survival in patients with bone metastasis of lung cancer. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Clinical orthopaedics and related research

VOLUME: 466

Page Numbers: 729-36

Journal Abbreviation: Clin. Orthop. Relat. Res.

ISSN: 0009-921X

DAY: 3

MONTH: 01

YEAR: 2008

Predictors of survival in patients with bone metastasis of lung cancer. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 75674

Predictors of survival in patients with bone metastasis of lung cancer. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Predictors of survival in patients with bone metastasis of lung cancer. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Predictors of survival in patients with bone metastasis of lung cancer.

AFFILIATION: Department of Orthopaedic Surgery, Aichi Cancer Center, 1-1 Kanokoden, Chikusa-ku, Nagoya, 464-8681, Japan, hsugiura@aichi-cc.jp.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Clin Orthop Relat Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Predictors of survival in patients with bone metastasis of lung cancer Related Publications

• Controversy about small peripheral lung adenocarcinomas: how should we manage them?
• Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer.
• LKB1 gene mutations in Japanese lung cancer patients.
• Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers.
• Predictors of survival in patients with bone metastasis of lung cancer.
• Subcategorization of lung cancer based on tumor size and degree of visceral pleural invasion.
• Subcategorization of resectable non-small cell lung cancer involving neighboring structures.